RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Takeda Pharmaceutical Co Stock

Takeda Pharmaceutical Co Equity 2024

Takeda Pharmaceutical Co Equity

7.27 T JPY

Ticker

4502.T

ISIN

JP3463000004

WKN

853849

In 2024, Takeda Pharmaceutical Co's equity was 7.27 T JPY, a 27.98% increase from the 5.68 T JPY equity in the previous year.

Takeda Pharmaceutical Co Aktienanalyse

What does Takeda Pharmaceutical Co do?

Takeda Pharmaceutical Co Ltd is a Japanese company that operates in the pharmaceutical industry. The company was founded in 1781 by Chobei Takeda as a traditional pharmacy specializing in herbal medicine. Nowadays, the company is a leading player in the global pharmaceutical industry. Business model: Takeda aims to help people worldwide through the development of groundbreaking therapies and drugs. The company has a strong research and development department that focuses on the discovery of new therapies and the improvement of existing medications. Takeda has made global partnerships and acquisitions to leverage the combination of science and technology and ensure better patient care. Divisions: Takeda operates in four main divisions: Gastrointestinal (GI), Oncology, Rare Diseases, and Neuroscience. In the GI division, the company is a global leader in the treatment of gastrointestinal diseases such as Crohn's disease and ulcerative colitis. The Oncology division aims to develop novel cancer therapies and provide patients with a higher quality of life. The Rare Diseases division specializes in the development of medications for rare diseases. The Neuroscience division focuses on developing medications to combat nervous system disorders such as Alzheimer's and Parkinson's. Products: Takeda's product range includes a variety of medications used worldwide to treat various diseases. One example is enzyme replacement therapy, which is administered to patients with a rare disease. Another example is Entyvio, a medication used to treat Crohn's disease and ulcerative colitis. Takeda also has medications in the Oncology division, such as Adcetris, a therapeutic agent against certain lymphomas and leukemia. In summary, Takeda Pharmaceutical Co Ltd is a leading company in the global pharmaceutical industry. The company's business model is based on the development of groundbreaking therapies and medications to improve patient care. With a focus on the GI, Oncology, Rare Diseases, and Neuroscience divisions, Takeda offers a variety of products for the treatment of various diseases. Takeda Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Takeda Pharmaceutical Co's Equity

Takeda Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Takeda Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Takeda Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Takeda Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Takeda Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Takeda Pharmaceutical Co stock

What is the equity of Takeda Pharmaceutical Co this year?

Takeda Pharmaceutical Co has equity of 7.27 T JPY this year.

What was the equity of Takeda Pharmaceutical Co compared to the previous year?

The equity of Takeda Pharmaceutical Co has increased/decreased by 27.98% increased compared to the previous year.

What impact does a high equity have on investors of Takeda Pharmaceutical Co?

A high equity is advantageous for investors of Takeda Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Takeda Pharmaceutical Co?

A low equity can be a risk for investors of Takeda Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Takeda Pharmaceutical Co affect the company?

An increase in equity of Takeda Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Takeda Pharmaceutical Co affect the company?

A reduction in equity of Takeda Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Takeda Pharmaceutical Co?

Some factors that can affect the equity of Takeda Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Takeda Pharmaceutical Co so important for investors?

The equity of Takeda Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Takeda Pharmaceutical Co take to change the equity?

To change equity, Takeda Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Takeda Pharmaceutical Co pay?

Over the past 12 months, Takeda Pharmaceutical Co paid a dividend of 192 JPY . This corresponds to a dividend yield of about 4.66 %. For the coming 12 months, Takeda Pharmaceutical Co is expected to pay a dividend of 185.23 JPY.

What is the dividend yield of Takeda Pharmaceutical Co?

The current dividend yield of Takeda Pharmaceutical Co is 4.66 %.

When does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Takeda Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 185.23 JPY are expected. This corresponds to a dividend yield of 4.49 %.

In which sector is Takeda Pharmaceutical Co located?

Takeda Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Takeda Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Takeda Pharmaceutical Co from 12/1/2024 amounting to 98 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Takeda Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Takeda Pharmaceutical Co in the year 2023?

In the year 2023, Takeda Pharmaceutical Co distributed 184 JPY as dividends.

In which currency does Takeda Pharmaceutical Co pay out the dividend?

The dividends of Takeda Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Takeda Pharmaceutical Co stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Takeda Pharmaceutical Co

Our stock analysis for Takeda Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takeda Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.